BioSpace News Archive

Amendola Communications, a nationally recognized, award-winning healthcare and health IT public relations and marketing firm, announced that TransformativeMed has engaged the agency to provide strategic PR and content marketing services.

According to Coherent Market Insights, the global electronic hearing protection devices market is expected to be valued at US$ 441.2 million in 2019, and is projected to exhibit a CAGR of 8.0% over the forecast period.

Shanghai ChemPartner announced the appointment of Jie Jack Li, Ph.D. as a Vice President of Discovery Chemistry at the Company headquarters in Shanghai, China.

The Chartis Group, a leading provider of comprehensive advisory services and analytics to the healthcare industry, is pleased to announce that LaTonya O’Neal has joined the firm.

About Shandong Fontacea Pharmaceutical Co. Ltd. Fontacea is a biopharmaceutical company dedicated to research, development and commercialization of innovative medicines for the global market, conveniently located in the Jining Hightech Zone, China, with a biopharmaceutical technology research & development center in Jinan.

The Administration announced two new proposed rules to address the critical organ supply crisis in America by expanding reimbursable expenses for living donors, establishing quality metrics for Organ Procurement Organizations and increasing the supply of transplantable deceased donor kidneys; and the National Kidney Foundation applauds these efforts to help the nearly 95,000 Americans waiting on a life-saving kidney transplant.

The National Safety Council is saddened to see a 2% rise in total worker deaths – 5,250 in 2018 compared to 5,147 in 2017 – according to data released by the Bureau of Labor Statistics.

DiaMedica Therapeutics Inc. announced dosing of the first patient in its REDUX Phase II study of DM199 for the treatment of Chronic Kidney Disease.

Michael J. Biercuk, founder and CEO of Q-CTRL, will describe how quantum sensors may provide exceptional new capabilities to the warfighter at the Office of Naval Research (ONR) on Jan. 13, 2020, as part of the ONR’s 2020 Distinguished Lecture Series.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the ILLUMINATE-A Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase (GO) in development for the treatment of primary hyperoxaluria type 1 (PH1), met its primary efficacy endpoint and all tested secondary endpoints